These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37908927)

  • 1. Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-Analysis.
    Karrar HR; Nouh MI; Nouh YI; Nouh MI; Khan Alhindi AS; Hemeq YH; Aljameeli AM; Aljuaid JA; Alzahrani SJ; Alsatami AA; Alkredees MA; Almuqati AO; Abanmi SN; Alshehri AM
    Cureus; 2023 Sep; 15(9):e46091. PubMed ID: 37908927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.
    Karagiannis T; Avgerinos I; Liakos A; Del Prato S; Matthews DR; Tsapas A; Bekiari E
    Diabetologia; 2022 Aug; 65(8):1251-1261. PubMed ID: 35579691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?
    Meng Z; Yang M; Wen H; Zhou S; Xiong C; Wang Y
    Front Endocrinol (Lausanne); 2023; 14():1121387. PubMed ID: 37051199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials.
    Patel H; Khunti K; Rodbard HW; Bajaj HS; Bray R; Kindracki Z; Rodríguez Á
    Diabetes Obes Metab; 2024 Feb; 26(2):473-481. PubMed ID: 37853960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.
    Weibel S; Rücker G; Eberhart LH; Pace NL; Hartl HM; Jordan OL; Mayer D; Riemer M; Schaefer MS; Raj D; Backhaus I; Helf A; Schlesinger T; Kienbaum P; Kranke P
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012859. PubMed ID: 33075160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.
    Nauck MA; D'Alessio DA
    Cardiovasc Diabetol; 2022 Sep; 21(1):169. PubMed ID: 36050763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
    Heise T; Mari A; DeVries JH; Urva S; Li J; Pratt EJ; Coskun T; Thomas MK; Mather KJ; Haupt A; Milicevic Z
    Lancet Diabetes Endocrinol; 2022 Jun; 10(6):418-429. PubMed ID: 35468322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials.
    Cai W; Zhang R; Yao Y; Wu Q; Zhang J
    Front Public Health; 2024; 12():1277113. PubMed ID: 38356942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial.
    Qin W; Yang J; Ni Y; Deng C; Ruan Q; Ruan J; Zhou P; Duan K
    Endocrine; 2024 Jun; ():. PubMed ID: 38850440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastrointestinal adverse events of tirzepatide in the treatment of type 2 diabetes mellitus: A meta-analysis and trials sequential analysis.
    Tong K; Yin S; Yu Y; Yang X; Hu G; Zhang F; Liu Z
    Medicine (Baltimore); 2023 Oct; 102(43):e35488. PubMed ID: 37904345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weight loss efficiency and safety of tirzepatide: A Systematic review.
    Lin F; Yu B; Ling B; Lv G; Shang H; Zhao X; Jie X; Chen J; Li Y
    PLoS One; 2023; 18(5):e0285197. PubMed ID: 37141329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice.
    Bradley CL; McMillin SM; Hwang AY; Sherrill CH
    Ann Pharmacother; 2023 Jul; 57(7):822-836. PubMed ID: 36367094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme.
    Boye KS; Thieu VT; Sapin H; Lee CJ; Landó LF; Brown K; Bray R; Wiese RJ; Patel H; Rodríguez Á; Yu M
    Diabetes Ther; 2023 Nov; 14(11):1833-1852. PubMed ID: 37526908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of tirzepatide as novel treatment for type 2 diabetes: A systematic review and meta-analysis of randomized clinical trials.
    Permana H; Yanto TA; Hariyanto TI
    Diabetes Metab Syndr; 2022 Nov; 16(11):102640. PubMed ID: 36274410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
    Ludvik B; Giorgino F; Jódar E; Frias JP; Fernández Landó L; Brown K; Bray R; Rodríguez Á
    Lancet; 2021 Aug; 398(10300):583-598. PubMed ID: 34370970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials.
    de Mesquita YLL; Pera Calvi I; Reis Marques I; Almeida Cruz S; Padrao EMH; Carvalho PEP; da Silva CHA; Cardoso R; Moura FA; Rafalskiy VV
    Int J Obes (Lond); 2023 Oct; 47(10):883-892. PubMed ID: 37460681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse Events Related to Tirzepatide.
    Mishra R; Raj R; Elshimy G; Zapata I; Kannan L; Majety P; Edem D; Correa R
    J Endocr Soc; 2023 Feb; 7(4):bvad016. PubMed ID: 36789109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the Dual Glucose‐Dependent Insulinotropic Peptide/Gulcagon‐like Peptide 1 Receptor Agonist Tirzepatide on Lipid Profile and Waist Circumference: A Systematic Review and Meta‐analysis.
    Yu D; Shen S; Zhang J; Wang Q
    Clin Ther; 2023 Aug; 45(8):787-796. PubMed ID: 37455226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis.
    Zeng Q; Xu J; Mu X; Shi Y; Fan H; Li S
    Front Endocrinol (Lausanne); 2023; 14():1214334. PubMed ID: 37908750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.